Cargando…

Intensifying Antiretroviral Therapy With Raltegravir and Maraviroc During Early Human Immunodeficiency Virus (HIV) Infection Does Not Accelerate HIV Reservoir Reduction

Background. Persistent human immunodeficiency virus (HIV) within the CD4(+) T-cell reservoir is an obstacle to eradication. We hypothesized that adding raltegravir and maraviroc to standard combination antiretroviral therapy (cART) during early HIV infection could substantially reduce viral reservoi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ostrowski, Mario, Benko, Erika, Yue, Feng Yun, Kim, Connie J., Huibner, Sanja, Lee, Terry, Singer, Joel, Pankovich, Jim, Laeyendecker, Oliver, Kaul, Rupert, Kandel, Gabor, Kovacs, Colin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2015
Materias:	Major Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621663/ https://www.ncbi.nlm.nih.gov/pubmed/26512359 http://dx.doi.org/10.1093/ofid/ofv138

Ejemplares similares

Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification
por: Ananworanich, Jintanat, et al.
Publicado: (2015)

Clinical and Mucosal Immune Correlates of HIV-1 Semen Levels in Antiretroviral-Naive Men
por: Osborne, Brendan J. W., et al.
Publicado: (2017)

Transcriptional Changes in CD8(+) T Cells During Antiretroviral Therapy Intensified With Raltegravir
por: Ouyang, Zhengyu, et al.
Publicado: (2015)

Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial
por: Lafeuillade, Alain, et al.
Publicado: (2014)

Impact of Raltegravir or Efavirenz on Cell-Associated Human Immunodeficiency Virus-1 (HIV-1) Deoxyribonucleic Acid and Systemic Inflammation in HIV-1/Tuberculosis Coinfected Adults Initiating Antiretroviral Therapy
por: Delagreverie, Héloïse M, et al.
Publicado: (2020)

IL-10-Producing B Cells Are Induced Early in HIV-1 Infection and Suppress HIV-1-Specific T Cell Responses
por: Liu, Jun, et al.
Publicado: (2014)

A Subset of Extreme Human Immunodeficiency Virus (HIV) Controllers Is Characterized by a Small HIV Blood Reservoir and a Weak T-Cell Activation Level
por: Canouï, Etienne, et al.
Publicado: (2017)

Maraviroc Intensification Modulates Atherosclerotic Progression in HIV-Suppressed Patients at High Cardiovascular Risk. A Randomized, Crossover Pilot Study
por: Francisci, Daniela, et al.
Publicado: (2019)

Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial
por: Kityo, Cissy, et al.
Publicado: (2018)

Changes in Waist Circumference in HIV-Infected Individuals Initiating a Raltegravir or Protease Inhibitor Regimen: Effects of Sex and Race
por: Bhagwat, Priya, et al.
Publicado: (2018)

HIV resistance to raltegravir
por: Clavel, François
Publicado: (2009)

Maraviroc in the treatment of HIV infection
por: Ray, Neelanjana
Publicado: (2009)

The Dietary Inflammatory Index Is Not Associated With Gut Permeability or Biomarkers of Systemic Inflammation in HIV Immunologic Non-responders
por: Malazogu, Fat, et al.
Publicado: (2021)

Oral Pre-Exposure Prophylaxis by Anti-Retrovirals Raltegravir and Maraviroc Protects against HIV-1 Vaginal Transmission in a Humanized Mouse Model
por: Neff, C. Preston, et al.
Publicado: (2010)

The Semen Microbiome and Its Relationship with Local Immunology and Viral Load in HIV Infection
por: Liu, Cindy M., et al.
Publicado: (2014)

Household Contact Tracing With Intensified Tuberculosis and Human Immunodeficiency Virus Screening in South Africa: A Cluster-Randomized Trial( )
por: Martinson, Neil A, et al.
Publicado: (2021)

Maraviroc: the evidence for its potential in the management of HIV
por: Profit, Louise
Publicado: (2007)

Raltegravir in the management of HIV-infected patients
por: Stellbrink, Hans-Jürgen
Publicado: (2009)

Immunogenicity of COVID-19 vaccines and their effect on HIV reservoir in older people with HIV
por: Matveev, Vitaliy A., et al.
Publicado: (2023)

Immunogenicity of COVID-19 vaccines and their effect on the HIV reservoir in older people with HIV
por: Matveev, Vitaliy A., et al.
Publicado: (2023)

Treatment Success Following Standard Antibiotic Treatment for Bacterial Vaginosis Is Not Associated With Pretreatment Genital Immune or Microbial Parameters
por: Armstrong, Eric, et al.
Publicado: (2023)

Aspirin Use for Primary and Secondary Prevention in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Patients
por: Suchindran, Sujit, et al.
Publicado: (2014)

Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies
por: Squires, Kathleen, et al.
Publicado: (2017)

Human Immunodeficiency Virus (HIV) and Aging: Multimorbidity in Older People With HIV in One Nonurban Southeastern Ryan White HIV/AIDS Program Clinic
por: Arant, Elizabeth C, et al.
Publicado: (2020)

A Case of Long-Term Seronegative Human Immunodeficiency Virus (HIV) Infection: The Importance of the Humoral Response to HIV
por: Siemieniuk, Reed A. C., et al.
Publicado: (2015)

Incidental Findings on Coronary Computed Tomography Angiography in Human Immunodeficiency Virus (HIV)-Positive and HIV-Negative Persons
por: Reinschmidt, Sara, et al.
Publicado: (2018)

Raltegravir: first in class HIV integrase inhibitor
por: Temesgen, Zelalem, et al.
Publicado: (2008)

Role of raltegravir in the management of HIV-1 infection
por: Okeke, N Lance, et al.
Publicado: (2011)

Activation and gut-homing of peripheral T cells in HIV immunologic non-responders despite long term viral suppression
por: Rousseau, Rodney K., et al.
Publicado: (2021)

Immune parameters of HIV susceptibility in the female genital tract before and after penile-vaginal sex
por: Mohammadi, Avid, et al.
Publicado: (2022)

Effect of Social Determinants of Health on Uncontrolled Human Immunodeficiency Virus (HIV) Infection Among Persons With HIV in San Francisco, California
por: Melo, Jason S, et al.
Publicado: (2022)

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
por: Eron, Joseph J., et al.
Publicado: (2013)

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study
por: Castagna, Antonella, et al.
Publicado: (2014)

US Human Immunodeficiency Virus (HIV) Practitioners’ Recommendations Regarding Condomless Sex in the Era of HIV Pre-Exposure Prophylaxis and Treatment as Prevention
por: Schreier, Travis, et al.
Publicado: (2019)

Cumulative Human Immunodeficiency Virus (HIV)-1 Viremia Is Associated With Increased Risk of Multimorbidity Among US Women With HIV, 1997–2019
por: Morton, Zoey P, et al.
Publicado: (2022)

Geospatial Analysis of Time to Human Immunodeficiency Virus (HIV) Diagnosis and Adult HIV Testing Coverage Highlights Areas for Intervention in the US Southeast
por: Matthews, Lynn T, et al.
Publicado: (2023)

Stable HIV Reservoir Despite Prolonged Low-Dose Mycophenolate to Limit CD4+ T-cell Proliferation
por: Schiffer, Joshua T, et al.
Publicado: (2022)

Mortality, Human Immunodeficiency Virus (HIV) Transmission, and Growth in Children Exposed to HIV in Rural Zimbabwe
por: Evans, Ceri, et al.
Publicado: (2020)

Reduced Baseline Sensitivity to Maraviroc Inhibition Among R5 HIV-1 Isolates From Individuals With Severe Immunodeficiency
por: Karlsson, Ulf, et al.
Publicado: (2016)

Lack of Awareness of Human Immunodeficiency Virus (HIV) Infection: Problems and Solutions With Self-reported HIV Serostatus of Men Who Have Sex With Men
por: Sanchez, Travis H., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7rpv8po3id59suabvl4gah45mn